Ricardo Alvim1, Karan Nagar1, Sudeep Das2, Souhil Lebdai1, Nathan Wong1, Alexander Somma1, Christopher Hughes1, Jasmine Thomas1, Sébastien Monette3, Avigdor Scherz4, Kwanghee Kim1, Jan Grimm2, Jonathan A Coleman5. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, New York, NY, USA. 4. Department of Plant and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel. 5. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: colemanj@mskcc.org.
Abstract
BACKGROUND: Evaluating the efficacy of focal therapy for prostate cancer is limited by current approaches and may be improved with biological imaging techniques. OBJECTIVE: We assessed whether positron emission tomography/computed tomography with gallium-68-labeled prostate-specific membrane antigen (68Ga-PSMA PET/CT) can be used to predict relapse after vascular-targeted photodynamic therapy (VTP). DESIGN, SETTING, AND PARTICIPANTS: A total of 1×106 LNCaP cells were grafted subcutaneously in the flanks of 6-8-wk-old SCID mice. Of 24 mice with measurable tumors 6 wk after tumor implantation, 20 were treated with VTP (150mW/cm2) to ablate the tumors. Blood prostate-specific antigen (PSA) levels were assessed, and ⁶⁸Ga-PSMA PET/CT images were performed 1 d before VTP and 1 and 4 wk after. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Local tumor relapse was evaluated by histology, and tumors were analyzed by prostate-specific membrane antigen (PSMA) and PSA immunohistochemistry. T tests and Kruskal-Wallis tests were used to determine significance. RESULTS AND LIMITATIONS: Four weeks after VTP, 11 (65%) mice had complete responses and six (35%) had tumor relapses confirmed by histology (hematoxylin and eosin, and PSMA immunohistochemistry). All mice with local relapse had positive 68Ga-PSMA PET/CT findings 4 wk after VTP; all complete responders did not. One week after VTP, the relapse detection sensitivity of 68Ga-PSMA PET/CT was 75%, whereas the sensitivity of PSA was only 33%. Compared with controls, relapsed tumors had a three-fold reduction in the number of cells with strong PSA staining by immunohistochemistry (1.5% vs 4.5%; p=0.01). CONCLUSIONS: In a preclinical prostate cancer model, we show that 68Ga-PSMA PET/CT can identify and predict relapse earlier than blood PSA level. These findings support further testing in clinical trials. PATIENT SUMMARY: Positron emission tomography/computed tomography with gallium-68-labeled prostate-specific membrane antigen may be used to follow and evaluate treatment outcomes in men who receive focal therapy for prostate cancer.
BACKGROUND: Evaluating the efficacy of focal therapy for prostate cancer is limited by current approaches and may be improved with biological imaging techniques. OBJECTIVE: We assessed whether positron emission tomography/computed tomography with gallium-68-labeled prostate-specific membrane antigen (68Ga-PSMA PET/CT) can be used to predict relapse after vascular-targeted photodynamic therapy (VTP). DESIGN, SETTING, AND PARTICIPANTS: A total of 1×106 LNCaP cells were grafted subcutaneously in the flanks of 6-8-wk-old SCID mice. Of 24 mice with measurable tumors 6 wk after tumor implantation, 20 were treated with VTP (150mW/cm2) to ablate the tumors. Blood prostate-specific antigen (PSA) levels were assessed, and ⁶⁸Ga-PSMA PET/CT images were performed 1 d before VTP and 1 and 4 wk after. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Local tumor relapse was evaluated by histology, and tumors were analyzed by prostate-specific membrane antigen (PSMA) and PSA immunohistochemistry. T tests and Kruskal-Wallis tests were used to determine significance. RESULTS AND LIMITATIONS: Four weeks after VTP, 11 (65%) mice had complete responses and six (35%) had tumor relapses confirmed by histology (hematoxylin and eosin, and PSMA immunohistochemistry). All mice with local relapse had positive 68Ga-PSMA PET/CT findings 4 wk after VTP; all complete responders did not. One week after VTP, the relapse detection sensitivity of 68Ga-PSMA PET/CT was 75%, whereas the sensitivity of PSA was only 33%. Compared with controls, relapsed tumors had a three-fold reduction in the number of cells with strong PSA staining by immunohistochemistry (1.5% vs 4.5%; p=0.01). CONCLUSIONS: In a preclinical prostate cancer model, we show that 68Ga-PSMA PET/CT can identify and predict relapse earlier than blood PSA level. These findings support further testing in clinical trials. PATIENT SUMMARY: Positron emission tomography/computed tomography with gallium-68-labeled prostate-specific membrane antigen may be used to follow and evaluate treatment outcomes in men who receive focal therapy for prostate cancer.
Authors: Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-05-15 Impact factor: 9.236
Authors: Scott P Kelly; Philip S Rosenberg; William F Anderson; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook Journal: Eur Urol Date: 2016-07-27 Impact factor: 20.096
Authors: Abdel-Rahmène Azzouzi; Sébastien Vincendeau; Eric Barret; Antony Cicco; François Kleinclauss; Henk G van der Poel; Christian G Stief; Jens Rassweiler; Georg Salomon; Eduardo Solsona; Antonio Alcaraz; Teuvo T Tammela; Derek J Rosario; Francisco Gomez-Veiga; Göran Ahlgren; Fawzi Benzaghou; Bertrand Gaillac; Billy Amzal; Frans M J Debruyne; Gaëlle Fromont; Christian Gratzke; Mark Emberton Journal: Lancet Oncol Date: 2016-12-20 Impact factor: 41.316
Authors: Heinz H Coenen; Antony D Gee; Michael Adam; Gunnar Antoni; Cathy S Cutler; Yasuhisa Fujibayashi; Jae Min Jeong; Robert H Mach; Thomas L Mindt; Victor W Pike; Albert D Windhorst Journal: Nucl Med Biol Date: 2017-10-02 Impact factor: 2.408
Authors: Isabel Rauscher; Tobias Maurer; Wolfgang P Fendler; Wieland H Sommer; Markus Schwaiger; Matthias Eiber Journal: Cancer Imaging Date: 2016-06-08 Impact factor: 3.909
Authors: Peter Bankhead; Maurice B Loughrey; José A Fernández; Yvonne Dombrowski; Darragh G McArt; Philip D Dunne; Stephen McQuaid; Ronan T Gray; Liam J Murray; Helen G Coleman; Jacqueline A James; Manuel Salto-Tellez; Peter W Hamilton Journal: Sci Rep Date: 2017-12-04 Impact factor: 4.379
Authors: Birthe Heitkötter; Konrad Steinestel; Marcel Trautmann; Inga Grünewald; Peter Barth; Heidrun Gevensleben; Martin Bögemann; Eva Wardelmann; Wolfgang Hartmann; Kambiz Rahbar; Sebastian Huss Journal: Oncotarget Date: 2018-01-04
Authors: Lucas Nogueira; Andrew T Tracey; Ricardo Alvim; Peter Reisz; Avigdor Scherz; Jonathan A Coleman; Kwanghee Kim Journal: Molecules Date: 2020-11-19 Impact factor: 4.411